Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Licence extension for insulin analogue

  • Comment
The licence for the short-acting insulin analogue insulin gluisine (Apidra) has been expanded to include use in the treatment of children six years or older with diabetes mellitus, where treatment with insulin is required.

Insulin gluisine, made by sanofi-aventis, is the latest rapid acting insulin analogue that can be used as a prandial insulin with a basal insulin.

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.